MedTrace Logo

The Effect of Tang Ning Tongluo Formula in Type 2 Diabetics Clinical Analysis

NCT02174042 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-09-11

No results posted yet for this study

Summary

The aim of this retrospective study is to review and describe safety and efficacy of Tang Ning Tong Luo capsule.

Conditions

  • General Disorders and Administration Site Conditions

Interventions

DRUG

Tangning Tongluo Capsule

Taken drugs 3 times a day, with each time 3 grains

Sponsors & Collaborators

  • Guizhou Bailing Group Pharmaceutical Co Ltd

    lead INDUSTRY

Principal Investigators

  • Wenshu Teng, Dr. · ICMJE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-08-31
Completion
2014-09-30

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02174042 on ClinicalTrials.gov